A fast acting and safe Ebola vaccine has been developed by scientists and this vaccine shows its effect against the strain with only one dose.

An interdisciplinary team from The University of Texas Medical Branch at Galveston and Profectus BioSciences Inc. has made the vaccine. As per the researchers, the vaccine is effective against Ebola with a single dose in a nonhuman primate. It is being tested in the Galveston National Laboratory,

This laboratory is the only completely operational Biosafety Level 4 laboratory on an academic campus in the United States. According to UTMB professor Thomas Geisbert, there is a possibility that findings might open the way for the identification and manufacture of safer, single dose, high efficiency vaccines in order to combat present and future Ebola outbreaks.

The researchers said that the vaccine employs a virus not harmful to human being called vesicular stomatitis virus. To deal with any possible safety concerns related with this vaccine, the researchers developed two next generation candidate vaccines. These have further weakened forms of the vaccine.

The researchers said that both of these vaccines generated about ten-fold lower level of virus in the blood than to the first generation vaccine. According to Chief Scientific Officer John Eldridge, the findings demonstrate that their candidate vaccines given full, single dose protection from a lethal amount of the Makona strain of Ebola virus.

As per the researchers, both weakened vaccines contain features of the Mayinga strain of Ebola virus. The new West African Makona strain and the original 1976 Mayinga strain are somewhat similar. According to the researchers, it was essential to test their candidate vaccines on the Makona strain to make sure that even small differences between the strains didn't impact the efficiency of the vaccine.